Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT04137107 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 220 participants, started 2020-06-17 and due to reach its primary completion in 2026-02-28. Interventions recorded: Oxaliplatin; Duloxetine Hydrochloride; Duloxetine; Quality-of-Life Assessment; Questionnaire Administration; Placebo. Conditions listed: Stage II Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8. Primary outcome: Prevention of sensory oxaliplatin-induced peripheral neuropathy (OIPN) response (Phase II); Prevention of sensory oxaliplatin-induced peripheral neuropathy (OIPN) response (Phase III); Chronic neuropathic pain response (Phase III). Colorectal eligibility wording from the registry: "* Stage II-III colorectal cancer patients scheduled to receive oxaliplatin 510 mg/m\^2 (cumulative dose) over 12 weeks as a component of adjuvant leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin (FOLFOX) treatment, in which patients are scheduled to receive oxaliplatin 85 mg/m\^". Sites: Guam, United States. No results are recorded here; the registry entry is the source.